Study adds support for single-dose HPV vaccine regimen

A single-dose human papillomavirus (HPV) vaccine was highly effective in a randomized controlled trial of 2,275 women in Kenya

The trial's lead investigator, Dr Ruanne Barnabas, said the results could help the World Health Organization achieve its goal of vaccinating 90 percent of 15-year-old girls against HPV by 2030

Currently, only 15% of women worldwide are vaccinated against HPV

At the time of the study, Barnabas was a professor of global health at the University of Washington School of Medicine in Seattle

Results from the "KEN-SHE" trial will be published Monday, April 11 in the New England Journal of Medicine's journal Evidence

"These findings are a game-changing finding that may substantially reduce the incidence of cervical cancer caused by HPV and make single-dose HPV vaccination a high-value, high-impact public health intervention for our It works," said

The findings further support the adoption of a single-dose HPV vaccine, which may increase low-income and Accessibility in middle-income countries

"HPV vaccines are a powerful tool for reducing cervical cancer, but too many women and girls in low- and middle-income countries do not have access to them," said Dull

Most sexually active men and women will get HPV at some point in their lives, and some will get it repeatedly

While nine out of 10 HPV infections clear up on their own within two years, other infections lead to cancers of the reproductive system, primarily cervical cancer

Worldwide, a woman dies from cervical cancer every two minutes

In the trial, women aged 15 to 20 were randomly assigned to one therapy and followed from December 2018 to June 2021

Participants were randomized into three treatment groups:

• 760 people were vaccinated with bivalent vaccine covering both HPV strains (16/18), accounting for 70% of total cases

• 758 people were vaccinated with invaluable vaccines covering seven HPV strains (16/18/31/33/45/52/58), accounting for 90% of total cases

• 757 people were vaccinated against meningococcal meningitis

  
  

After 18 months, the bivalent vaccine was 97.

The researchers say more studies need to be done to test the duration of the vaccine

"This trial brings new energy to the elimination of cervical cancer

One of the driving forces behind the trial, the researchers said, was the cervical cancer ward at Kenyatta National Hospital in Nairobi
.
They said they wanted the ward to be vacant
.

"I believe in my lifetime I will see cervical cancer eliminated," said Dr Maricianah Onono of the Kenya Institute of Medical Research
.
"So, let's do it - give every woman a chance!"